A pneumococcal vaccine given as one dose to children with sickle cell disease
Compares a new pneumococcal vaccine with a licensed one in children with sickle cell disease.
Key facts
- Who runs it
- Sanofi
- Where
- Atlanta, Houston, New Brunswick, and Omaha, United StatesSee the 5 sitesAlso in 1 other country, 2 sites
- Trial code
- NCT07247188
- U1111-1319-0153
- Registry title
- Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 100 people, planned
- Started
- 20 Jan 2026
- Expected to end
- 7 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- PCV21
- 20vPCV
- Record updated
- 15 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 2 to 17 years with sickle cell disease. It tests the safety of a single dose of a new pneumococcal vaccine (PCV21) against a licensed one (20vPCV).
- Age
- 2 to 17 years
- Sex
- Boys and girls can both join. A girl who could become pregnant must agree to use effective contraception or abstinence and have a negative pregnancy test.
- Disease stage
- Sickle cell disease documented in the medical record.
- Earlier treatment
- Cannot have had any dose of 20vPCV. Children under 6 must have had at least 3 doses of pneumococcal conjugate vaccine and no PPSV23. Children 6 and older cannot have had PPSV23 less than 5 years ago or a last PCV dose less than 8 weeks ago.
Main reasons for not taking part
- Known or suspected immune system weakness, or recent immunosuppressive treatment such as chemotherapy or radiation within 6 months
- Past confirmed pneumococcal (S. pneumoniae) infection
- History of seizures or serious neurological disorders
- Bleeding disorder, low platelets, or blood thinners that make a muscle injection unsafe
- Moderate or severe acute illness, or fever of 38.0°C (100.4°F) or higher on the day of vaccination
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- AGE
- Aged 2 to 17 years on the day of inclusion; TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS
- Participants who have a documented diagnosis of sickle cell disease (SCD) in their medical record; SEX, CONTRACEPTIVE/BARRIER METHOD AND PREGNANCY TESTING REQUIREMENTS
- A participant is eligible to participate if the participant is not pregnant or breastfeeding and one of the following conditions applies:; Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be pre-menarchal or surgically sterile. OR; Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration. A participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 25 hours before the study intervention; INFORMED CONSENT
- Assent form has been signed and dated by the participant (based on local regulations), and, if applicable, informed consent form has been signed and dated by the parent(s) or another legally acceptable representative (LAR) and by an independent witness, if required by local regulations; OTHER INCLUSIONS
- Participant and parent(s)/LAR are able to attend all scheduled visits and to comply with all study procedures
Who cannot take part
- Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion; PRIOR/CONCOMITANT THERAPY
- For children and adolescents aged ≥ 6 years: receipt of PPSV23 < 5 years before study vaccination or last PCV dose < 8 weeks before study vaccination
- Receipt of any vaccine in the 4 weeks preceding the study intervention administration or planned receipt of any vaccine in the 4 weeks following the study intervention administration, except for US licensed influenza vaccination, which may be received at least 2 weeks before or 2 weeks after study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines, as applicable per local recommendations
- Receipt of an oral or injectable antibiotic therapy for any acute illness within 72 hours prior to the first blood draw; PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE
- Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure; OTHER EXCLUSIONS For children (2 to 5 YoA) only
- MEDICAL CONDITIONS
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy
- History of microbiologically confirmed S. pneumoniae infection or disease
- History of seizure or significant stable or progressive neurological disorders such as inflammatory nervous system diseases, encephalopathy, and cerebral palsy
- Known systemic hypersensitivity to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided; For children/adolescents (6 to 17 YoA) only
- Laboratory-confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent/LAR, contraindicating intramuscular (IM) injection
- For children aged < 6 years: receipt of < 3 doses of pneumococcal conjugate vaccine or any dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23)
- Receipt of at least one dose of 20vPCV
- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- Being in an emergency setting
- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study; For children/adolescents (6 to 17 YoA) only
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
Where in United States
Also in 1 other country, 2 sites
- Atlanta, GeorgiaHospital not named in the registryTaking people
- Atlanta, GeorgiaHospital not named in the registryTaking people
- Houston, TexasHospital not named in the registryTaking people
- New Brunswick, New JerseyHospital not named in the registryTaking people
- Omaha, NebraskaHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.
The 2 groups in the trial
- Investigated Vaccine: PCV21Treatment being tested
Participants will receive 1 intramuscular injection of the pneumococcal vaccine
Treatment: PCV21
- Comparator Vaccine: 20vPCVExisting treatment, for comparison
Participants will receive 1 intramuscular injection of the pneumococcal vaccine
Treatment: 20vPCV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
- Plain-language title
- A pneumococcal vaccine given as one dose to children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07247188, who can take part
- Record updated
- 15 April 2026